Navigation Links
Neuralstem chief scientific officer to take part in World Stem Cell Summit plenary session
Date:10/1/2010

Neuralstem, Inc. (NYSE Amex: CUR) announced that the Chairman of its Board of Directors and Chief Scientific Officer, Dr. Karl Johe, PhD, will take part in a plenary discussion entitled, Current and Future Clinical Trials and Stem Cell Therapies, at the World Stem Cell Summit on October 5, in Detroit, MI (http://www.worldstemcellsummit.com/summit-agenda). Dr. Johe is the creator of Neuralstems neural stem cell technology.

The panel will be moderated by Dr. Eva Feldman, PhD, MD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, and includes as well Dr. Jonathan Glass, MD, Professor of Neurology & Director Emory ALS Center Emory University, and Dr. Nicholas Boulis, MD, Assistant Professor Neurosurgery Emory University.

Neuralstem is currently sponsoring a Phase I trial of its spinal cord stem cells in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrigs disease) at the ALS Center at Emory University, in Atlanta, GA. Dr. Feldman is the Principal Investigator, Dr. Glass is the Site Principal Investigator and Dr. Boulis is the Co-Investigator and Neurosurgeon.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in a Phase I safety clinical trial for Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. In addition to ALS, the company is targeting major central nervous system diseases, including traumatic spinal cord injury, ischemic spastic paraplegia, and Huntington's disease. The company has also submitted an IND application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Through its proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company plans to initiate clinical trials to treat Alzheimer's disease and major depression with its lead compound, as well as pursue additional indications, including traumatic brain injury, posttraumatic stress syndrome, stroke and schizophrenia.


'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Related medicine news :

1. Neuralstem stem cells survive and differentiate into neurons in rats with stroke
2. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
3. Neuralstem updates clinical trial progress
4. National Institute of General Medical Sciences chief wins prestigious public service award
5. FDA Chief Says More Egg Recalls Possible
6. Spectrum Surgical Instruments Appoints President, Chief Operating Officer
7. DKI Direct Appoints Greg Lewis as Chief Marketing Officer
8. BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role
9. Steri -7 Appoints BioNeutral Group Inc. Chief Scientist Dr. Andy Kielbania for Expanded Role
10. Former NIH Chief Joins Children's National Medical Center
11. Martek Biosciences Chief Scientific Officer, Dr. Norman Salem, 2010 Recipient of Alex Leaf Distinguished Scientist Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... An in-depth computational analysis of genetic variants implicated in both ... genes that may explain why susceptibility to one of the disorders could place individuals ... today in the journal npj Schizophrenia. , “There is a wealth of genomic ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... ... to The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite ... Medical District with easy access to Highway 121. , As the practice has grown, ...
(Date:2/24/2017)... ... , ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 ... image mannequin art competition. Selected from 15 submissions from around the nation, the top ... 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This year, ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle ... hosted their Military Wedding Giveaway, with the winning couple announced on Feb. 14, ... services generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... clinician-based audience, will be participating in Rare Disease Day events, hosted by the ... addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Februar 2017 LG Innotek hat heute die ... Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... zwischen 200 und 280 nm und eignet sich damit für ... ihre DNA zerstört. Das Produkt von LG Innotek erzeugt ... ...
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die Guian ... Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden Strategien ... einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
(Date:2/23/2017)... New York , February 23, 2017 ... implications arising from increasing caseload for varicose veins in ... across the globe are prompting the adoption of endovenous ... study on global endovenous laser therapy market, ... towards aftereffects of lifestyle choices and consequences of obesity ...
Breaking Medicine Technology: